---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-022068"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:59:36.208157+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics reports Q4 net loss of $60.1M; announces $350M private placement; paltusotine NDA on track for 2H 2024

## Summary
- Net loss for Q4 2023 was $60.1M vs $45.0M in Q4 2022; full-year net loss $214.5M vs $163.9M in 2022.
- Cash, equivalents, and investments totaled $558.6M as of Dec 31, 2023; $350M private placement extends runway into 2028.
- Phase 3 PATHFNDR-2 topline results for paltusotine in acromegaly expected March 2024; NDA submission planned 2H 2024.
- Phase 2 paltusotine in carcinoid syndrome full topline results expected 1H 2024; initial data from 27 patients reported Dec 2023.
- R&D expenses rose to $168.5M for FY2023 from $130.2M in FY2022, driven by higher personnel and outside services costs.

## SEC filing metadata
- accession: 0000950170-24-022068
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017024022068/0000950170-24-022068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017024022068/crnx-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-022068
- JSON: https://secwatch.observer/filing/0000950170-24-022068.json
- Plain text: https://secwatch.observer/filing/0000950170-24-022068.txt

## Key facts
- Earnings Releases
  Crinetics Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $4.0 million, net income net loss of $214.5 million.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $4.0 million
  - Net income: net loss of $214.5 million
  - Result: reported results
  source text: ended December 31, 2022 and $1.0 million for the year ended December 31, 2022. This loss was derived from the company’s investment in Radionetics Oncology, Inc. • Revenues were $4.0 million for the full year ended December 31, 2023, compared to $4.7 million for the same period in 2022. There were no revenues for the three months ended December 31, 2023, compared to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017024022068/0000950170-24-022068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.